The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults
Open accessAbstract
PURPOSE: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS: Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS: We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION: The revised RANO 2.0 criteria refine response assessment in gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationEANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationOstrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac202 · Cited by 1,565
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationBrandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationAlbert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Self-citationConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
van den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Self-citationModified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Self-citationTaal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak‐Kragten, A. T., Sillevis Smitt, P. A. E., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465
Self-citationKickingereder, P., Isensee, F., Tursunova, I., Petersen, J., Neuberger, U., Bonekamp, D., Brugnara, G., Schell, M., Kessler, T., Foltyn, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30098-1 · Cited by 454
Self-citationKarschnia, P., Young, J. S., Dono, A., Häni, L., Sciortino, T., Bruno, F., Juenger, S. T., Teske, N., Morshed, R. A., Haddad, A. F., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac193 · Cited by 384
Self-citationImmediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Self-citationHorbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00679-w · Cited by 312
Self-citationBerger, T. R., Wen, P. Y., Lang-Orsini, M., & Chukwueke, U. N. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2844 · Cited by 297
Self-citationNayak, L., DeAngelis, L. M., Brandes, A. A., Peereboom, D. M., Galanis, E., Lin, N. U., Soffietti, R., Macdonald, D. R., Chamberlain, M., Perry, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox029 · Cited by 244
Self-citationMiller, J. J., Gonzalez Castro, L. N., McBrayer, S., Weller, M., Cloughesy, T., Portnow, J., Andronesi, O., Barnholtz-Sloan, J. S., Baumert, B. G., Berger, M. S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac207 · Cited by 242
Self-citationShah, G. D., Kesari, S., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 195
Self-citationChang, K., Beers, A. L., Bai, H. X., Brown, J. M., Ly, K. I., Li, X., Senders, J. T., Kavouridis, V. K., Boaro, A., Su, C., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz106 · Cited by 179
Self-citationGalanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
Self-citationProgression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
Nowosielski, M., Wiestler, B., Goebel, G., Hutterer, M., Schlemmer, H. P., Stockhammer, G., Wick, W., Bendszus, M., & Radbruch, A. (2014) · Neurology · doi:10.1212/wnl.0000000000000402 · Cited by 114
Self-citationCharacterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
Melguizo‐Gavilanes, I., Bruner, J. M., Guha‐Thakurta, N., Hess, K. R., & Puduvalli, V. K. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1774-5 · Cited by 109
Pérez‐Larraya, J. G., Lahutte, M., Petrirena, G. J., Reyes-Botero, G., González-Aguilar, A., Houillier, C., Guillevin, R., Sanson, M., Hoang‐Xuan, K., & Delattre, J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos070 · Cited by 106
Wick, W., Chinot, O. L., Bendszus, M., Mason, W. P., Henriksson, R., Saran, F. H., Nishikawa, R., Révil, C., Kerloëguen, Y., & Cloughesy, T. F. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now091 · Cited by 104
Self-citationEllingson, B. M., Leu, K., Pope, W. B., Lai, A., Nghiemphu, P. L., Liau, L. M., & Cloughesy, T. F. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov225.24 · Cited by 98
Self-citationIncidence of pseudoprogression in low-grade gliomas treated with radiotherapy
van West, S. E., de Bruin, H. G., van de Langerijt, B., Swaak‐Kragten, A. T., van den Bent, M. J., & Taal, W. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now194 · Cited by 94
Huang, R. Y., Rahman, R. M., Ballman, K. V., Felten, S. J., Anderson, S. K., Ellingson, B. M., Nayak, L., Lee, E. Q., Abrey, L. E., Galanis, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3040 · Cited by 75
Self-citationEllingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox193 · Cited by 69
Self-citationEllingson, B. M., Kim, G. H. J., Brown, M., Lee, J., Salamon, N., Steelman, L., Hassan, I. S. A., Pandya, S. S., Chun, S., Linetsky, M., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab256 · Cited by 68
Self-citationYoussef, G., Rahman, R. M., Bay, C. P., Wang, W., Lim-Fat, M. J., Arnaout, O. M., Bi, W. L., Cagney, D. N., Chang, Y.-S., Cloughesy, T. F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01579 · Cited by 67
Self-citationGahrmann, R., van den Bent, M. J., van der Holt, B., Vernhout, R. M., Taal, W., Vos, M. J., de Groot, J. C., Beerepoot, L. V., Buter, J., Flach, Z. H., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now311 · Cited by 51
Holdhoff, M., Ye, X., Piotrowski, A. F., Strowd, R. E., III, Seopaul, S., Lu, Y., Barker, N. J., Sivakumar, A., Rodríguez, F. J., Grossman, S. A., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03037-3 · Cited by 44
Imaging Glioblastoma Posttreatment
Strauß, S., Meng, A., Ebani, E. J., & Chiang, G. C.-Y. (2020) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2020.09.010 · Cited by 37
Boxerman, J. L., Zhang, Z., Safriel, Y., Rogg, J. M., Wolf, R. L., Mohan, S., Marques, H., Sorensen, A. G., Gilbert, M. R., & Barboriak, D. P. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy049 · Cited by 35
Self-citationRadiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio
Nowosielski, M., Ellingson, B. M., Chinot, O. L., Garcia, J., Révil, C., Radbruch, A., Nishikawa, R., Mason, W. P., Henriksson, R., Saran, F. H., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox162 · Cited by 34
Self-citationBoxerman, J. L., & Ellingson, B. M. (2015) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000054 · Cited by 23
Self-citationEllingson, B. M., Gerstner, E. R., Lassman, A. B., Chung, C. D., Colman, H., Cole, P. E., Leung, D. K.-W., Allen, J. E., Ahluwalia, M. S., Boxerman, J. L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac086 · Cited by 22
Self-citationFu, R. F., Szidonya, L. K., Barajas, R., Ambady, P., Várallyay, C. G., & Neuwelt, E. A. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac027 · Cited by 21
Cited by
Advances of MR imaging in glioma: What the neurosurgeon needs to know
Falk Delgado, A. (2025) · Acta Neurochirurgica · doi:10.1007/s00701-025-06593-6 · Cited by 14
Metadata
- Authors
- Wen, P. Y., van den Bent, M., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., Huang, R., Lassman, A. B., Mehta, M., Molinaro, A. M., Preusser, M., Rahman, R., Shankar, L. K., Stupp, R., Villanueva-Meyer, J. E., Wick, W., Macdonald, D. R., Reardon, D. A., Vogelbaum, M. A., & Chang, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2023-11-20
- Volume
- 41
- Issue
- 33
- Pages
- 5187-5199
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4387163062
- Cited by
- 519
- References
- 40
- FWCI
- 73.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.